207 related articles for article (PubMed ID: 33991036)
1. The effects of infliximab in treating idiopathic inflammatory myopathies: A review article.
Ge Y; Li S; Chen F; He L; Li C; Lu X; Wang G
Dermatol Ther; 2021 Jul; 34(4):e14976. PubMed ID: 33991036
[TBL] [Abstract][Full Text] [Related]
2. A systematic review on biological therapies in juvenile idiopathic inflammatory myopathies: an evidence gap in precision medicine.
Marrani E; Abu-Rumeileh S; Mastrolia MV; Maccora I; Pagnini I; Simonini G
Clin Exp Rheumatol; 2022 Feb; 40(2):457-470. PubMed ID: 34905479
[TBL] [Abstract][Full Text] [Related]
3. Juvenile Dermatomyositis: Advances in Pathogenesis, Assessment, and Management.
Leung AKC; Lam JM; Alobaida S; Leong KF; Wong AHC
Curr Pediatr Rev; 2021; 17(4):273-287. PubMed ID: 33902423
[TBL] [Abstract][Full Text] [Related]
4. Idiopathic Inflammatory Myopathies.
Balan S; Madan S
Indian J Pediatr; 2023 Nov; ():. PubMed ID: 37919486
[TBL] [Abstract][Full Text] [Related]
5. Local injection of infliximab into calcinosis lesions in patients with juvenile dermatomyositis (JDM): a clinical trial.
Shiari R; Khalili M; Zeinali V; Shashaani N; Samami M; Moghaddamemami FH
Pediatr Rheumatol Online J; 2024 Jan; 22(1):2. PubMed ID: 38166943
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis.
Zhen C; Hou Y; Zhao B; Ma X; Dai T; Yan C
Front Immunol; 2022; 13():1051609. PubMed ID: 36578492
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients.
Campanilho-Marques R; Deakin CT; Simou S; Papadopoulou C; Wedderburn LR; Pilkington CA;
Arthritis Res Ther; 2020 Apr; 22(1):79. PubMed ID: 32293539
[TBL] [Abstract][Full Text] [Related]
8. Juvenile dermatomyositis associated with autoantibodies to small ubiquitin-like modifier activating enzyme: a report of 4 cases from North India and a review of literature.
Vignesh P; Barman P; Basu S; Mondal S; Ishran B; Kumrah R; Dod A; Garg R; Rawat A; Singh S
Immunol Res; 2023 Feb; 71(1):112-120. PubMed ID: 36278969
[TBL] [Abstract][Full Text] [Related]
9. Polymyositis and dermatomyositis - challenges in diagnosis and management.
Yang SH; Chang C; Lian ZX
J Transl Autoimmun; 2019 Dec; 2():100018. PubMed ID: 32743506
[TBL] [Abstract][Full Text] [Related]
10. Angioedema-like presentation as the presenting finding of juvenile myositis and juvenile dermatomyositis in 2 patients.
Karaca Ö; Güngör M; Sakarya Güneş A; Eser Şimşek I; Anık Y; Kara B
Int J Rheum Dis; 2022 May; 25(5):617-625. PubMed ID: 35238477
[TBL] [Abstract][Full Text] [Related]
11. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.
Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE
Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672
[TBL] [Abstract][Full Text] [Related]
12. Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.
Spencer CH; Rouster-Stevens K; Gewanter H; Syverson G; Modica R; Schmidt K; Emery H; Wallace C; Grevich S; Nanda K; Zhao YD; Shenoi S; Tarvin S; Hong S; Lindsley C; Weiss JE; Passo M; Ede K; Brown A; Ardalan K; Bernal W; Stoll ML; Lang B; Carrasco R; Agaiar C; Feller L; Bukulmez H; Vehe R; Kim H; Schmeling H; Gerstbacher D; Hoeltzel M; Eberhard B; Sundel R; Kim S; Huber AM; Patwardhan A;
Pediatr Rheumatol Online J; 2017 Jun; 15(1):50. PubMed ID: 28610606
[TBL] [Abstract][Full Text] [Related]
13. Juvenile-onset clinically amyopathic dermatomyositis: an overview of recent progress in diagnosis and management.
Walling HW; Gerami P; Sontheimer RD
Paediatr Drugs; 2010; 12(1):23-34. PubMed ID: 20034339
[TBL] [Abstract][Full Text] [Related]
14. Juvenile Idiopathic Inflammatory Myopathies.
Huber AM
Pediatr Clin North Am; 2018 Aug; 65(4):739-756. PubMed ID: 30031496
[TBL] [Abstract][Full Text] [Related]
15. Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics.
Moghadam-Kia S; Oddis CV; Aggarwal R
Clin Rev Allergy Immunol; 2017 Feb; 52(1):81-87. PubMed ID: 26767526
[TBL] [Abstract][Full Text] [Related]
16. Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review.
Paik JJ; Lubin G; Gromatzky A; Mudd PN; Ponda MP; Christopher-Stine L
Clin Exp Rheumatol; 2023 Mar; 41(2):348-358. PubMed ID: 35766013
[TBL] [Abstract][Full Text] [Related]
17. Juvenile dermatomyositis: a tertiary center experience.
Barut K; Aydin PO; Adrovic A; Sahin S; Kasapcopur O
Clin Rheumatol; 2017 Feb; 36(2):361-366. PubMed ID: 28058540
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis.
Riley P; McCann LJ; Maillard SM; Woo P; Murray KJ; Pilkington CA
Rheumatology (Oxford); 2008 Jun; 47(6):877-80. PubMed ID: 18403404
[TBL] [Abstract][Full Text] [Related]
19. Corticosteroids in Myositis and Scleroderma.
Postolova A; Chen JK; Chung L
Rheum Dis Clin North Am; 2016 Feb; 42(1):103-18, ix. PubMed ID: 26611554
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis.
Gordon PA; Winer JB; Hoogendijk JE; Choy EH
Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD003643. PubMed ID: 22895935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
